ATE448481T1 - Selektionsverfahren für eine durch das austesten einer ppard aktivierenden wirkung charakterisierten substanz und arzneistoff - Google Patents
Selektionsverfahren für eine durch das austesten einer ppard aktivierenden wirkung charakterisierten substanz und arzneistoffInfo
- Publication number
- ATE448481T1 ATE448481T1 AT02747685T AT02747685T ATE448481T1 AT E448481 T1 ATE448481 T1 AT E448481T1 AT 02747685 T AT02747685 T AT 02747685T AT 02747685 T AT02747685 T AT 02747685T AT E448481 T1 ATE448481 T1 AT E448481T1
- Authority
- AT
- Austria
- Prior art keywords
- ppard
- accelerate
- medicinal
- testing
- substance
- Prior art date
Links
- 239000000126 substance Substances 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 102100038824 Peroxisome proliferator-activated receptor delta Human genes 0.000 abstract 3
- 108091008765 peroxisome proliferator-activated receptors β/δ Proteins 0.000 abstract 3
- 230000004913 activation Effects 0.000 abstract 2
- 210000003470 mitochondria Anatomy 0.000 abstract 2
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 abstract 1
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 abstract 1
- 230000001539 anorectic effect Effects 0.000 abstract 1
- 230000003178 anti-diabetic effect Effects 0.000 abstract 1
- 239000003472 antidiabetic agent Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000002438 mitochondrial effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000007254 oxidation reaction Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 230000035924 thermogenesis Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
- G01N33/5079—Mitochondria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001216502 | 2001-07-17 | ||
| PCT/JP2002/007277 WO2003008967A1 (en) | 2001-07-17 | 2002-07-17 | Method of selecting substance characterized by assaying ppard activating effect and drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE448481T1 true ATE448481T1 (de) | 2009-11-15 |
Family
ID=19050972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02747685T ATE448481T1 (de) | 2001-07-17 | 2002-07-17 | Selektionsverfahren für eine durch das austesten einer ppard aktivierenden wirkung charakterisierten substanz und arzneistoff |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7396642B2 (de) |
| EP (1) | EP1416273B1 (de) |
| JP (2) | JP3888998B2 (de) |
| KR (3) | KR101021817B1 (de) |
| CN (3) | CN102912016A (de) |
| AT (1) | ATE448481T1 (de) |
| AU (1) | AU2002318743B2 (de) |
| CA (1) | CA2452246A1 (de) |
| DE (1) | DE60234348D1 (de) |
| WO (1) | WO2003008967A1 (de) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007186515A (ja) * | 2003-05-02 | 2007-07-26 | Takara Bio Inc | 治療剤 |
| JP4525221B2 (ja) * | 2004-07-16 | 2010-08-18 | アステラス製薬株式会社 | 受容体リガンド同定法 |
| EP3489257A1 (de) | 2004-07-23 | 2019-05-29 | Acceleron Pharma Inc. | Actrii-rezeptor-polypeptide, verfahren und zusammensetzungen |
| PT1973559E (pt) | 2005-11-23 | 2013-02-19 | Acceleron Pharma Inc | Antagonistas de activina-actriia e utilizações para promover o crescimento ósseo |
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TWI584815B (zh) | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| TWI548647B (zh) | 2007-02-02 | 2016-09-11 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| TWI606062B (zh) | 2007-02-09 | 2017-11-21 | 艾瑟勒朗法瑪公司 | 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途 |
| CN107412734A (zh) | 2007-09-18 | 2017-12-01 | 阿塞勒隆制药公司 | 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途 |
| JP6078228B2 (ja) * | 2008-05-27 | 2017-02-08 | オリバー ディー． ボス， | ヒト骨格筋における褐色脂肪細胞前駆体 |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| TWI626945B (zh) | 2008-08-14 | 2018-06-21 | 艾瑟勒朗法瑪公司 | 使用ｇｄｆ阱以增加紅血球水平 |
| EP2387412A4 (de) | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | Verfahren zur erhöhung des adiponectin-spiegels |
| MX355042B (es) * | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
| CN102656187A (zh) | 2009-06-12 | 2012-09-05 | 阿塞勒隆制药公司 | 截短的actriib-fc融合蛋白 |
| US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| KR20130132824A (ko) | 2010-11-08 | 2013-12-05 | 악셀레론 파마 인코포레이티드 | Actriia 결합제 및 이의 용도 |
| CA2867922A1 (en) | 2011-11-10 | 2013-05-16 | Energesis Pharmaceuticals, Inc. | Brown adipocyte progenitors in human skeletal muscle |
| EP2914277B1 (de) | 2012-11-02 | 2017-09-13 | Celgene Corporation | Activin-actrii-antagonisten und verwendungen zur behandlung von knochen- und anderen erkrankungen |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| TWI730949B (zh) | 2014-12-03 | 2021-06-21 | 美商西建公司 | 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途 |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| CN107638569A (zh) * | 2016-07-21 | 2018-01-30 | 上海聿健生物科技有限公司 | 增强褐色脂肪细胞产热效率的方法和应用 |
| USD824964S1 (en) | 2016-08-19 | 2018-08-07 | Samsung Electronics Co., Ltd. | Refrigerator door |
| JP2020528900A (ja) * | 2017-07-27 | 2020-10-01 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 体脂肪低減のためのプロスタサイクリン受容体アゴニスト |
| CN116875603B (zh) * | 2023-09-06 | 2023-12-08 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向线粒体解偶联蛋白mRNA的miRNA分子及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6300362B1 (en) * | 1990-07-25 | 2001-10-09 | Novartis Ag (Formerly Sandoz Ltd.) | Stabilized pharmaceutical compositions comprising acid donors |
| US6022897A (en) * | 1995-04-25 | 2000-02-08 | The Salk Institute For Biological Studies | Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof |
| AU712607B2 (en) | 1996-02-02 | 1999-11-11 | Merck & Co., Inc. | Method of treating diabetes and related disease states |
| WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
| ES2320181T3 (es) * | 1997-07-24 | 2009-05-19 | Astellas Pharma Inc. | Composiciones farmaceuticas que tienen un efecto reductor del colesterol. |
| GB9914977D0 (en) | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
-
2002
- 2002-07-17 WO PCT/JP2002/007277 patent/WO2003008967A1/ja not_active Ceased
- 2002-07-17 CN CN201210361724XA patent/CN102912016A/zh active Pending
- 2002-07-17 KR KR1020097009737A patent/KR101021817B1/ko not_active Expired - Fee Related
- 2002-07-17 AT AT02747685T patent/ATE448481T1/de not_active IP Right Cessation
- 2002-07-17 US US10/483,627 patent/US7396642B2/en not_active Expired - Fee Related
- 2002-07-17 DE DE60234348T patent/DE60234348D1/de not_active Expired - Lifetime
- 2002-07-17 KR KR1020107026032A patent/KR101106518B1/ko not_active Expired - Fee Related
- 2002-07-17 JP JP2003514257A patent/JP3888998B2/ja not_active Expired - Fee Related
- 2002-07-17 AU AU2002318743A patent/AU2002318743B2/en not_active Ceased
- 2002-07-17 CA CA002452246A patent/CA2452246A1/en not_active Abandoned
- 2002-07-17 CN CNB028144503A patent/CN100419425C/zh not_active Expired - Fee Related
- 2002-07-17 KR KR1020047000532A patent/KR100912852B1/ko not_active Expired - Fee Related
- 2002-07-17 CN CNA2008100909108A patent/CN101259276A/zh active Pending
- 2002-07-17 EP EP02747685A patent/EP1416273B1/de not_active Revoked
-
2008
- 2008-06-19 US US12/142,652 patent/US20080287544A1/en not_active Abandoned
-
2011
- 2011-09-30 JP JP2011217652A patent/JP2012062315A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR101106518B1 (ko) | 2012-01-20 |
| KR20110002097A (ko) | 2011-01-06 |
| KR20040017300A (ko) | 2004-02-26 |
| KR100912852B1 (ko) | 2009-08-18 |
| KR20090074800A (ko) | 2009-07-07 |
| CN1533504A (zh) | 2004-09-29 |
| JP2012062315A (ja) | 2012-03-29 |
| EP1416273B1 (de) | 2009-11-11 |
| US20080287544A1 (en) | 2008-11-20 |
| US20040265817A1 (en) | 2004-12-30 |
| EP1416273A4 (de) | 2005-06-15 |
| JP3888998B2 (ja) | 2007-03-07 |
| DE60234348D1 (de) | 2009-12-24 |
| EP1416273A1 (de) | 2004-05-06 |
| CN100419425C (zh) | 2008-09-17 |
| WO2003008967A1 (en) | 2003-01-30 |
| US7396642B2 (en) | 2008-07-08 |
| KR101021817B1 (ko) | 2011-03-17 |
| CN102912016A (zh) | 2013-02-06 |
| JPWO2003008967A1 (ja) | 2004-11-11 |
| CN101259276A (zh) | 2008-09-10 |
| CA2452246A1 (en) | 2003-01-30 |
| AU2002318743B2 (en) | 2008-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE448481T1 (de) | Selektionsverfahren für eine durch das austesten einer ppard aktivierenden wirkung charakterisierten substanz und arzneistoff | |
| Amin et al. | Contact urticaria syndrome | |
| Al‐Mubarak et al. | Comparative evaluation of adjunctive oral irrigation in diabetics | |
| Satoh et al. | Augmented agonist-induced Ca (2+)-sensitization of coronary artery contraction in genetically hypertensive rats. Evidence for altered signal transduction in the coronary smooth muscle cells. | |
| JPS62223115A (ja) | 歯周病治療剤 | |
| SE8504580D0 (sv) | Platt-liknande preparat | |
| DE69533470D1 (de) | Aus mehreren einzeleinheiten zusammengesetztes pharmazeutisches präparat, das einen protonenpumpeninhibitor enthält | |
| US8344031B2 (en) | Compositions for the treatment of signs of aging | |
| DE69409483D1 (de) | Biaromatische Propinylverbindungen, sie enthaltende pharmazeutische Zubereitungen und Kosmetika sowie deren Verwendungen | |
| JP2005535665A (ja) | 虚血および再灌流損傷を防止する方法 | |
| BR0116370A (pt) | Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente. | |
| US8163313B2 (en) | Compositions containing amines and use thereof | |
| NL970008I1 (nl) | Derivaat van een weefselplasminogeenactivator. | |
| WO2015153184A1 (en) | Method for screening trp channels | |
| ES2564187T3 (es) | Agentes de modulación de glutamato en el tratamiento de trastornos mentales | |
| ATE242005T1 (de) | P277 peptidanaloge, pharmazeutische zusammenstellung davon zur behandlung und diagnose von diabetes | |
| EA199700381A1 (ru) | Диароматические соединения пропинила или диенила, промежуточные соединения, фармацевтические и косметические композиции на основе указанных соединений и применение косметических композиций | |
| Dahl et al. | Irritation test of tissue adhesives for facial prostheses | |
| JP2003267848A (ja) | サブスタンスｐアンタゴニストまたはｃｇｒｐアンタゴニストを含有するケラチン繊維のパーマネント変形のための組成物 | |
| KR920003981A (ko) | 항염증성 조성물 | |
| BR0309966A (pt) | Muteìnas de fator de crescimento placentário tipo 1, método de preparação e seus usos | |
| DK0821593T3 (da) | Konjugat af et aktivt middel, et protein og eventuelt et for kroppen ikke som fremmed anset nativt protein | |
| ES2587010T3 (es) | Composición cosmética destinada al cuidado de pieles dañadas | |
| CN112294975A (zh) | 接触性过敏原试剂组合及其用途 | |
| Mawhirt et al. | Patch testing and the evaluation of contact allergy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |